Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

16 Jan 2013

GeneTex to introduce new EasyBlot reagent

GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that they will be launching EasyBlot, a new secondary antibody reagent that eliminates the interference that has long plagued immunoprecipitation (IP) experiments when the IP and western blot primary antibodies are from the same host.

16 Jan 2013

Additional insights into workings of ALVAC vaccine against HIV

Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease.

11 Jan 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

11 Jan 2013

TSRI chemists develop new cell-marking method

Chemists at The Scripps Research Institute (TSRI) have found an easier way to perform one of the most fundamental tasks in molecular biology. Their new method allows scientists to add a marker to certain cells, so that these cells may be easily located and/or selected out from a larger cell population.

10 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Report shows how P. gingivalis manipulates body's immune system to disable normal processes

A new research report published in the Journal of Leukocyte Biology shows how the bacteria known for causing gum disease--Porphyromonas gingivalis--manipulates the body's immune system to disable normal processes that would otherwise destroy it. Specifically, the report shows that this pathogen prompts the production of the anti-inflammatory molecule Interleukin-10 (IL-10).

4 Jan 2013

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

3 Jan 2013

Adrenomed creates Adrecizumab to decrease death rates from sepsis

The German corporation Adrenomed AG today announced its intentions to contribute to the reduction of mortality from sepsis and septic shock. Sepsis is an advanced systemic infection that travels via the blood stream to many of the body's vital organs, which can lead to death and disability.

3 Jan 2013

Uncharacterized TLR plays key role in Toxoplasma gondii response

A previously uncharacterized toll-like receptor appears to play a crucial role in the innate immune response to Toxoplasma gondii infection and may promote host resistance, potentially leading to anti-parasite vaccines, say US researchers.

28 Dec 2012

Antibody type prognostic for myasthenia gravis patients

Patients who have myasthenia gravis are more likely to have a severe form of the disease and more difficulty achieving remission if they are seropositive for antibodies to muscle-specific kinase, report researchers.

24 Dec 2012

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

Acorda Therapeutics acquires Neuronex

Acorda Therapeutics, Inc. today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

21 Dec 2012

US FDA approves raxibacumab for treating inhalational anthrax

The US Food and Drug Administration have approved the monoclonal antibody raxibacumab for treatment of inhalational anthrax, caused by breathing in spores of Bacillus anthracis.

19 Dec 2012

Allakos closes $32M Series A financing to develop antibody-based therapeutics

Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.

17 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

Antibody News and Research

Further Reading

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

GeneTex to introduce new EasyBlot reagent

Additional insights into workings of ALVAC vaccine against HIV

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

TSRI chemists develop new cell-marking method

Adolescents may lose hepatitis B virus protection despite vaccination as infants

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

Report shows how P. gingivalis manipulates body's immune system to disable normal processes

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Adrenomed creates Adrecizumab to decrease death rates from sepsis

Uncharacterized TLR plays key role in Toxoplasma gondii response

Antibody type prognostic for myasthenia gravis patients

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

Acorda Therapeutics acquires Neuronex

US FDA approves raxibacumab for treating inhalational anthrax

Allakos closes $32M Series A financing to develop antibody-based therapeutics

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

Antibodies eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News